研究成果
2020~2024研究論文與期刊發表
|
日期 |
主題 |
作者 |
論文/期刊名稱 |
IF 分數 |
被引用 次數 |
|
2024 |
Tuberculosis notifications among citizens and non-citizens in Taiwan |
Lo H-Y, Huang Y-C, Chan P-C, Lee C-C, Chiang C-Y*. (通訊) |
Int J Tuberc Lung Dis |
3.4 |
0 |
|
2024 |
Radiographic characteristics of rifampicin-resistant tuberculosis in the STREAM stage 1 trial and their influence on time to culture conversion in the short regimen. |
Chiang C-Y, Bern H, Goodall R, Chien S-T, Rusen ID, Nunn A (第一) |
BMC Infectious Diseases |
3.7 |
1 |
|
2024 |
Mitigating treatment failure of pulmonary pre-extensively drug-resistant tuberculosis: the role of new and repurposed drugs |
Y. W. Huang, M. C. Yu, C. B. Lin, J. J. Lee, C. J. Jui Lin, S. T. Chien, C. H. Lee, C. Y. Chiang (通訊) |
J Microbiol Immunol Infect |
7.4 |
0 |
|
2024 |
Emerging insight of whole genome sequencing coupled with protein structure prediction into the pyrazinamide-resistance signature of Mycobacterium tuberculosis |
C. K. Huang, M. C. Yu, C. S. Hung and J. C. Lin (第一、通訊) |
Int J Antimicrob Agents |
10.8 |
1 |
|
2024 |
Effect of drug interactions with non-vitamin-K oral anticoagulants on thromboembolic events in patients with nonvalvular atrial fibrillation |
M.-C. L. Jin-Hua Chen, Tzu-Hsin Yen, Pei-Yu Huang, De-En Lu, Chih-Hsin Lee, Hsien-Chen Chang, Jann-Yuan Wang, Jen-Ai Lee (第一、通訊) |
Annals, Academy of Medicine, Singapore |
5.2 |
0 |
|
2024 |
Multiplexed Antibody Glycosylation Profiling Using Dual Enzyme Digestion and Liquid Chromatography-Triple Quadrupole Mass Spectrometry Method |
Y. H. Cheng, C. H. Lee, S. Y. Wang, C. Y. Chou, Y. J. Yang, C. C. Kao, et al. (第一、通訊) |
Mol Cell Proteomics |
7.0 |
0 |
|
2023 |
Risk factor analysis of postoperative complications after adjunctive pulmonary resection in patients with multidrug-resistant tuberculosis: A multi-institutional study |
W. L. Huang, S. T. Chien, M. C. Yu, B. S. Chang, Y. T. Yen, M. H. Wu and Y. L. Tseng |
J Microbiol Immunol Infect |
7.4 |
0 |
|
2023 |
Incremental yield of serial sputum examinations in the diagnosis of pulmonary tuberculosis in Taiwan: Findings of a pragmatic trial |
Chiang CY, Lin CB, Chien ST, Wang CH, Huang YW, Huang WC, Yu MC, Lee JJ, Rieder HL (第一) |
J Microbiol Immunol Infect |
7.4 |
0 |
|
2023 |
Prevention and management of tuberculosis in solid organ transplantation: A consensus statement of the transplantation society of Taiwan |
Chiang CY, Chen CH, Feng JY, Chiang YJ, Huang WC, Lin YJ, Huang YW, Wu HH, Lee PH, Lee MC et al (第一) |
J Formos Med Assoc |
3.2 |
1 |
|
2023 |
Alveolar deposition of inhaled fine particulate matter increased risk of severity of pulmonary tuberculosis in the upper and middle lobes. |
Makrufardi F, Bai KJ, Suk CW, Rusmawatiningtyas D, Chung KF, Chuang HC. |
ERJ open research |
4.6 |
1 |
|
2023 |
Isoniazid level and flu-like symptoms during rifapentine-based tuberculosis preventive therapy: A population pharmacokinetic analysis |
M. C. Lee, Y. Fujita, S. Muraki, H. L. Huang, C. H. Lee, J. Y. Wang and I. Ieiri |
Br J Clin Pharmacol |
3.7 |
4 |
|
2023 |
Serial electrocardiogram recordings revealed a high prevalence of QT interval prolongation in patients with tuberculosis receiving fluoroquinolones |
K. S. Ju, R. G. Lee, H. C. Lin, J. H. Chen, B. F. Hsu, J. Y. Wang, et al. (第一、通訊) |
J Formos Med Assoc |
3.2 |
1 |
|
2022 |
Assessment of TB patient cost – what about the mitigation strategy? |
Chiang C-Y*, Lin H-H, Fu H. (第一、通訊) |
Int J Tuberc Lung Dis |
3.4 |
0 |
|
2022 |
Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB |
Kokebu DM, Ahmed S, Moodliar R, Chiang C-Y, Torrea G, Van Deun A, Goodall RL, Rusen ID, Meredith SK, Nunn AJ. |
Int J Tuberc Lung Dis |
3.4 |
2 |
|
2022 |
Differential Impact of the rpoB Mutant on Rifampin and Rifabutin Resistance Signatures of Mycobacterium tuberculosis Is Revealed Using a Whole-Genome Sequencing Assay |
M. C. Yu, C. S. Hung, C. K. Huang, C. H. Wang, Y. C. Liang and J. C. Lin (第一、通訊) |
Microbiol Spectr |
3.7 |
2 |
|
2022 |
Nucleic acid amplification tests reduce delayed diagnosis and misdiagnosis of pulmonary tuberculosis. |
Feng JY, Lin CJ, Wang JY, Chien ST, Lin CB, Huang WC, Lee CH, Shu CC, Yu MC, Lee JJ, Chiang CY. (通訊) |
Scientific reports. |
4.6 |
1 |
|
2022 |
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. |
Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, Chiang CY, Conradie F, Gurumurthy M, Kirenga B, Kiria N, Meressa D, et al. |
Lancet |
168.9 |
44 |
|
2022 |
ECG monitoring in STREAM Stage 1: can we identify those at increased risk of QT prolongation? |
Hughes G, Bern H, Chiang CY, Goodall RL, Nunn AJ, Rusen ID, Meredith SK. |
Int J Tuberc Lung Dis. |
3.4 |
1 |
|
2022 |
Global availability of susceptibility testing for second-line anti-tuberculosis agents. |
Lazarchik A, Nyaruhirira AU, Chiang CY, Wares F, Horsburgh CR. |
Int J Tuberc Lung Dis. |
3.4 |
3 |
|
2022 |
Hemodialysis acutely altered interferon-gamma release assay test result and immune cell profile |
D. U. Putri, C. L. Chen, C. H. Wang, Y. M. Sue, P. C. Tseng, C. F. Lin, et al. (第一、通訊) |
J Microbiol Immunol Infect |
7.4 |
2 |
|
2022 |
Advantages of short-course rifamycin-based regimens for latent tuberculosis infection: an updated network meta-analysis |
T. R. Peng, J. H. Chen, Y. H. Chang, J. C. Shiang, M. C. Lee, C. H. Lee and J. Y. Wang (通訊) |
J Glob Antimicrob Resist |
4.35 |
2 |
|
2022 |
Tuberculosis treatment delay and nosocomial exposure remain important risks for patients undergoing regular hemodialysis |
M. Lu, Y. M. Sue, H. L. Hsu, J. F. Zhang, Y. J. Liu, Y. C. Yen, et al. (第一、通訊) |
J Microbiol Immunol Infect |
7.4 |
2 |
|
2022 |
Minimizing nephrotoxicity during multidrug-resistant tuberculosis treatment by the stepwise de-escalation of second-line injectables dosing intervals |
H. C. Lin, M. C. Yu, D. U. Putri, Y. S. Tsai, J. H. Chen and C. H. Lee (第一、通訊) |
Clin Microbiol Infect |
13.3 |
0 |
|
2022 |
Performance of Nucleic Acid Amplification Tests in Patients with Presumptive Pulmonary Tuberculosis in Taiwan |
W. C. Huang, C. B. Lin, S. T. Chien, J. Y. Wang, C. J. Lin, J. Y. Feng, et al. (通訊) |
Infect Dis Ther |
6.119 |
3 |
|
2022 |
Whole-Blood 3-Gene Signature as a Decision Aid for Rifapentine-based Tuberculosis Preventive Therapy |
H. L. Huang, J. Y. Lee, Y. S. Lo, I. H. Liu, S. H. Huang, Y. W. Huang, et al. |
Clin Infect Dis |
11.8 |
4 |
|
2022 |
Nucleic acid amplification tests reduce delayed diagnosis and misdiagnosis of pulmonary tuberculosis |
J. Y. Feng, C. J. Lin, J. Y. Wang, S. T. Chien, C. B. Lin, W. C. Huang, et al. (通訊) |
Sci Rep |
4.6 |
1 |
|
2022 |
Bisphosphonate Use Is Not Associated With Tuberculosis Risk Among Patients With Osteoporosis: A Nationwide Cohort Study |
J. H. Chen, C. H. Lee, M. R. Lee, P. Y. Huang, T. H. Yen, M. C. Lee, et al. (第一) |
J Clin Pharmacol |
2.9 |
1 |
|
2022 |
Performance of Nucleic Acid Amplification Tests in Patients with Presumptive Pulmonary Tuberculosis in Taiwan. |
Huang WC, Lin CB, Chien ST, Wang JY, Lin CJ, Feng JY, Lee CH, Shu CC, Yu MC, Lee JJ, Chiang CY. (通訊) |
Infect Dis Ther. |
6.1 |
3 |
|
2022 |
QT prolongation in the STREAM Stage 1 Trial. |
Hughes G, Bern H, Chiang CY, Goodall RL, Nunn AJ, Rusen ID, Meredith SK. |
Int J Tuberc Lung Dis. |
3.4 |
10 |
|
2022 |
Proteomic networks associated with tumor-educated macrophage polarization and cytotoxicity potentiated by heat-killed tuberculosis. |
Putri DU, Feng PH, Lin CF, Haryana SM, Soesatyo M, Lee KY, Han CL. (第一) |
Scientific reports. |
5.0 |
0 |
|
2022 |
Minimizing nephrotoxicity during multidrug-resistant tuberculosis treatment by the stepwise de-escalation of second-line injectables dosing intervals. |
Lin HC, Yu MC, Putri DU, Tsai YS, Chen JH, Lee CH. (第一、通訊) |
Clinical microbiology and infection |
13.3 |
0 |
|
2022 |
Associations between lung-deposited dose of particulate matter and culture-positive pulmonary tuberculosis pleurisy. |
Bai KJ, Tung NT, Hsiao TC, Chen TL, Chung KF, Ho SC, Tsai CY, Chen JK, Lee CN et al. (第一) |
Environ Sci Pollut Res Int. |
5.8 |
3 |
|
2022 |
Whole-blood 3-gene Signature as a Decision Aid for Rifapentine-based TB Preventive Therapy. |
Huang HL, Lee JY, Lo YS, Liu IH, Huang SH, Huang YW, Lee MR, Lee CH, Cheng MH, Lu PL, Wang JY, Yang JM, Chong IW. |
Clin Infect Dis. |
11.8 |
4 |
|
2021 |
Integrative utility of long read sequencing-based whole genome analysis and phenotypic assay on differentiating isoniazid-resistant signature of Mycobacterium tuberculosis. |
Yu MC, Hung CS, Huang CK, Wang CH, Liang YC, Lin JC. (第一、通訊) |
Journal of biomedical science. |
12.8 |
1 |
|
2021 |
Hemodialysis acutely altered interferon-gamma release assay test result and immune cell profile. |
Putri DU, Chen CL, Wang CH, Sue YM, Tseng PC, Lin CF, Tsai CW, Liu YJ, Lee CH. (第一、通訊) |
Journal of microbiology, immunology, and infection |
7.4 |
2 |
|
2021 |
Improving lung health in low-income and middle-income countries: from challenges to solutions. |
Meghji J, Mortimer K, Agusti A, Allwood BW, Asher I, Bateman ED, Bissell K, Bolton CE, Bush A, Celli B, Chiang CY, et al. |
Lancet |
168.9 |
146 |
|
2021 |
Biosafety and Proteome Profiles of Different Heat Inactivation Methods for Mycobacterium tuberculosis |
C. H. Wang, D. U. Putri, J. C. Lee, C. C. Liao, S. T. Tsao, A. L. Hsiao, et al (第一、通訊) |
Microbiol Spectr |
3.7 |
1 |
|
2021 |
Acquired Resistance to Isoniazid During Isoniazid Monotherapy in a Subject with Latent Infection Following Household Rifampicin-Resistant Tuberculosis Contact: A Case Report |
T. L. Li, T. H. Chan, C. H. Wang, R. Jou, M. C. Yu, D. U. Putri, et al. (第一、通訊) |
Infect Drug Resist |
4.2 |
1 |
|
2021 |
Determination of fluoroquinolones in dried plasma spots by using microwave-assisted extraction coupled to ultra-high performance liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring |
A. Brahmadhi, M. X. Chen, S. Y. Wang, Y. Y. Cho, M. C. Yu, C. H. Lee and I. L. Tsai (第一、通訊) |
J Pharm Biomed Anal |
3.6 |
13 |
|
2020 |
Green Light Committee and recommendations of World Health Organization |
Chiang C-Y. (第一、通訊) |
Int J Tuberc Lung Dis |
3.4 |
1 |
|
2020 |
The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis |
L. Martinez, O. Cords, C. R. Horsburgh, J. R. Andrews and T. B. C. S. C. Pediatric |
Lancet |
168.9 |
158 |
|
2020 |
The impact of smoking on TB treatment outcomes includes recurrent TB |
Chiang CY, Bam TS. (第一) |
Int J Tuberc Lung Dis |
3.4 |
5 |
|
2020 |
New diseases and old threats: lessons from tuberculosis for the COVID-19 response |
Dara M, Sotgiu G, Reichler MR, Chiang C-Y, Chee CBE, Migliori GB. |
Int J Tuberc Lung Dis |
3.4 |
50 |
|
2020 |
Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial. |
Phillips PPJ, Van Deun A, Ahmed S, Goodall RL, Meredith SK, Conradie F, Chiang CY, Rusen ID, Nunn AJ. |
BMC Med |
11.8 |
7 |
|
2020 |
Tackling the threat of COVID-19 in Africa: an urgent need for practical planning |
Chiang C-Y*, El Sony A. (第一、通訊) |
Int J Tuberc Lung Dis |
3.4 |
21 |
|
2020 |
The impact of COVID-19 and the restoration of tuberculosis services in the Western Pacific Region. |
Chiang CY, Islam T, Xu C, Chinnayah T, Garfin AMC, Rahevar K, Raviglione M. (第一) |
Eur Respir J |
24.9 |
31 |
|
2020 |
Advantage in privacy protection by using synchronous video observed treatment enhances treatment adherence among patients with latent tuberculosis infection. |
Chen SH, Wang I, Hsu HL, Huang CC, Liu YJ, Putri DU, Lee CH. (第一、通訊) |
Journal of infection and public health. |
7.5 |
11 |
|
2020 |
The looming threat of bedaquiline resistance in tuberculosis. |
Chiang CY, Trébu cq A, Piubello A, Rieder HL, Schwoebel V, Van Deun A. (第一) |
Eur Respir J |
24.9 |
3 |
|
2020 |
Identification and drug susceptibility testing for nontuberculous mycobacteria. |
Huang WC, Yu MC, Huang YW. |
J Formos Med Assoc. |
3.87 |
24 |
|
2020 |
Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis in Mongolia. |
Narmandakh E, Tumenbayar O, Borolzoi T, Erkhembayar B, Boldoo T, Dambaa N, Burneebaatar B, Nymadawa N, Mitarai S, Jav S, Chiang CY. (通訊) |
Antimicrob Agents Chemother. |
5.9 |
6 |
|
2020 |
Effect of ventilation improvement during a tuberculosis outbreak in under ventilated university buildings. |
Du CR, Wang SC, Yu MC, Chiu TF, Wang JY, Chuang PC, Jou R, Chan PC, Fang CT. |
Indoor Air |
6.6 |
48 |
|
2020 |
Progress in the roll-out of multidrug-resistant tuberculosis (MDR-TB) treatments. |
Heng M, Allmendinger S, Chiang CY, Trébucq A, Horsburgh CR |
Int J Tuberc Lung Dis |
3.4 |
2 |
|
2020 |
Comparison of the predictive outcomes for anti-tuberculosis drug-induced hepatotoxicity by different machine learning techniques. |
Lai NH, Shen WC, Lee CN, Chang JC, Hsu MC, Kuo LN, Yu MC, Chen HY. |
Comput Methods Programs Biomed. |
7.0 |
27 |
|
2020 |
Clinical impact of using fluoroquinolone with low antimycobacterial activity on treatment delay in tuberculosis: Hospital-based and population-based cohort study |
M. R. Lee, C. H. Lee, J. Y. Wang, S. W. Lee, J. C. Ko and L. N. Lee |
J Formos Med Assoc |
3.9 |
4 |
|
2020 |
World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward. |
Van Deun A, Decroo T, Tahseen S, Trébucq A, Schwoebel V, Ortuno-Gutierrez N, de Jong BC, Rieder HL, Piubello A, Chiang CY. (通訊) |
Int J Antimicrob Agents |
15.4 |
15 |